Raajit K. Rampal

Hematology | Oncology

530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 179 publications

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 30, 2026

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 02, 2026

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.

Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.

Journal: Leukemia

Published: March 20, 2026

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Journal: Haematologica

Published: March 20, 2026

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Journal: Future oncology (London, England)

Published: March 07, 2026

Fibrotic marrow limiting morphologic classification in MDS/MPN with SF3B1 mutation and thrombocytosis: diagnostic implications under the ICC 2022 framework.

Fibrotic marrow limiting morphologic classification in MDS/MPN with SF3B1 mutation and thrombocytosis: diagnostic implications under the ICC 2022 framework.

Journal: Virchows Archiv : an international journal of pathology

Published: February 24, 2026

Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.

Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.

Journal: Leukemia & lymphoma

Published: January 10, 2026

CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia.

CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia.

Journal: Blood cancer journal

Published: November 14, 2025

GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study.

GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study.

Journal: Haematologica

Published: September 08, 2025

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms.

Journal: Leukemia

Published: September 02, 2025

Results from a US modified Delphi consensus to define disease progression and disease modification in polycythemia Vera.

Results from a US modified Delphi consensus to define disease progression and disease modification in polycythemia Vera.

Journal: Annals of hematology

Published: August 12, 2025

Is doublet therapy becoming a standard of care in myelofibrosis?

Is doublet therapy becoming a standard of care in myelofibrosis?

Journal: Clinical advances in hematology & oncology : H&O

Published: July 29, 2025

Showing 1-12 of 179

Last Updated: 09/26/2026